Article

Iris Pharma develops new CNV model

Nice, France-Iris Pharma, which specializes in the research and development of preclinical products in the field of ophthalmology, developed a new choroidial neovascularization (CNV) model in rats by using an argon laser.

Nice, France-Iris Pharma, which specializes in the research and development of preclinical products in the field of ophthalmology, developed a new choroidial neovascularization (CNV) model in rats by using an argon laser.

This model is in addition to many other validated animal models with ocular angiogenesis: retinopathy of prematurity hyperoxia in pup mice; retinal vascular permeation, induced by vascular endothelium growth factor in rabbits; and corneal neovascularization models induced by chemical burn (alcohol and sodium hydroxide) in rats, mice, and rabbits, or by corneal sutures in rabbits.

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
© 2025 MJH Life Sciences

All rights reserved.